T 1701/22 (Obesity treatment with semaglutide/NOVO NORDISK) of 16.01.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T170122.20250116
- Date of decision
- 16 January 2025
- Case number
- T 1701/22
- Petition for review of
- -
- Application number
- 13737808.9
- IPC class
- A61P 3/04A61K 38/26
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of long-acting GLP-1 peptides
- Applicant name
- Novo Nordisk A/S
- Opponent name
- Teva Pharmaceutical Industries Ltd
Generics [UK] Limited
Galenicum Health S.L.U. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Selection of the closest prior art
Inventive step - (no) - Catchword
- -
Order
For these reasons it is decided that:
- The appeal is dismissed.